UCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases

NCT07410377 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Systemic Lupus Erythematosus
Inflammatory Myopathy

Interventions

BIOLOGICAL: UCAR-T cells

Sponsor

The Affiliated Hospital of Xuzhou Medical University

Collaborators

[object Object]